Item type |
文献 / Documents(1) |
公開日 |
2024-02-21 |
アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
出版社版DOI |
|
|
|
関連識別子 |
https://doi.org/10.1007/s11604-024-01529-z |
|
|
関連名称 |
10.1007/s11604-024-01529-z |
出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
タイトル |
|
|
タイトル |
Combined visual and quantitative assessment of somatostatin receptor scintigraphy for staging and restaging of neuroendocrine tumors |
著者 |
ウエキ, ユウヤ
大塚, 秀樹
大谷, 環樹
笠井, 亮佑
音見, 暢一
イケミツ, ダイキ
阿實, 翔太
国金, 大和
バンドウ, タカノリ
マツダ, ノリタケ
岡田, 泰行
高山, 哲治
原田, 雅史
|
抄録 |
|
|
内容記述 |
Purpose: Somatostatin receptor scintigraphy (SRS) using 111In-DTPA-DPhe1-octreotide (pentetreotide) has become an integral part of neuroendocrine neoplasm management. The lack of precise quantification is a disadvantage of SRS. This study aimed to adapt the standardized uptake value (SUV) to SRS, establish the SUV range for physiological uptake in the liver, kidney, and spleen, and elucidate the utility of combined visual and quantitative SRS assessment for staging and restaging of neuroendocrine tumors (NETs). Materials and methods: This study included 21 patients with NETs who underwent 111In-pentetreotide SRS. The SUV of physiological and pathological uptake was calculated using bone single-photon emission computed tomography (SPECT) quantitative analysis software (GI-BONE). For visual analysis, the primary and metastatic lesions were scored visually on planar and SPECT images using a five-point scale. We assessed the relationships between the SUVs of the liver, kidney, and spleen in the dual phase, and among quantitative indices, visual score, and pathological lesions classification. Results: Sixty-three NEN lesions were evaluated. The mean±standard deviation maximum SUVs (SUVmax) were liver: 4 h, 2.6±1.0; 24 h, 2.2±1.0; kidney: 4 h, 8.9±1.8; 24 h, 7.0±2.0; and spleen; 4 h, 11.3±4.5; 24 h, 11.5±7.6. Higher SUVmax was significantly associated with higher visual scores on dual-phase SPECT (4 h, p <0.001; 24 h, p <0.001) (4 h: scores 3 and 4, p <0.05; scores 3 and 5: p <0.01; scores 4 and 5: p <0.01; 24 h: scores 3 and 4, p=0.0748; scores 3 and 5: p <0.01; scores 4 and 5: p <0.01). Conclusion: We adapted the SUV to SRS and established the range of SUV for physiological uptake in the liver, kidney, and spleen. Combined visual and quantitative assessment is useful for imaging individual lesions in greater detail, and may serve as a new tumor marker of SRS for staging and restaging of NETs. |
キーワード |
|
|
主題 |
111In-pentetreotide |
キーワード |
|
|
主題 |
Somatostatin receptor (SSTR) |
キーワード |
|
|
主題 |
Somatostatin receptor scintigraphy (SRS) |
キーワード |
|
|
主題 |
Neuroendocrine tumors (NETs) |
キーワード |
|
|
主題 |
Becquerel calibration factor (BCF) |
キーワード |
|
|
主題 |
Standardized uptake value (SUV) |
書誌情報 |
en : Japanese Journal of Radiology
巻 42,
号 5,
p. 519-535,
発行日 2024-02-12
|
収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
1867108X |
収録物ID |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
18671071 |
収録物ID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA12375935 |
出版者 |
|
|
出版者 |
Japan Radiological Society |
出版者 |
|
|
出版者 |
Springer Nature |
備考 |
|
|
値 |
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use (https://www.springernature.com/gp/open-research/policies/accepted-manuscript-terms), but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: https://doi.org/10.1007/s11604-024-01529-z |
EID |
|
|
識別子 |
405060 |
言語 |
|
|
言語 |
eng |